RayzeBio develops novel peptide mimetic binders to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/13/2022 | Series D | $159.75MM | $xx.xx | $599.64MM | Ally Bridge Group, Laurion Capital Management, Sands Capital, Sofinnova Investments, Soleus Capital, Viking Global Investors, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
63,972,982
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Laurion Capital Management, Sands Capital, Sofinnova Investments, Soleus Capital, Viking Global Investors, Wellington Management
|
||||||
06/15/2021 | Series C | $99.63MM | $xx.xx | $651.39MM | Acuta Capital Partners, Alexandria Venture Investments, Cg X, Cormorant Asset Management, Deerfield Management, Lifesci Venture Partners, Logos Capital, Orbimed, Perceptive Advisors, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors, Vivo Capital | |
Price per Share
$xx.xx
Shares Outstanding
23,999,996
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acuta Capital Partners, Alexandria Venture Investments, Cg X, Cormorant Asset Management, Deerfield Management, Lifesci Venture Partners, Logos Capital, Orbimed, Perceptive Advisors, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors, Vivo Capital
|
||||||
12/08/2020 | Series B | $96.86MM | $xx.xx | $237.83MM | Alexandria Venture Investments, Cormorant Asset Management, Lifesci Venture Partners, Logos Capital, Orbimed, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
46,666,672
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Cormorant Asset Management, Lifesci Venture Partners, Logos Capital, Orbimed, Redmile Group, Samsara Biocapital, Venbio Partners, Venrock Healthcare Capital Partners, Versant Ventures, Viking Global Investors
|
||||||
10/14/2020 | Series A | $41.51MM | $xx.xx | $55.35MM | Samsara Biocapital, Venbio Partners, Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
45,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Samsara Biocapital, Venbio Partners, Versant Ventures
|